Abbott posts 2024 medical device sales gains following structural heart, CGM launches
For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve repair implant and FDA clearances for two over-the-counter blood sugar trackers, among other products.
Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects new device ...
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...
Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...
Abbott's Q4 sales reached $10.97 billion, with 8.8% organic growth. EPS met expectations at $1.34, driven by strong ...
Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...
For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.
Abbott Laboratories ABT reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.34, in line with the Zacks ...
A hospital in Saudi Arabia announced today that it completed the world's first robotic-assisted implantation of the Abbott ...
For the current quarter ending in March, Abbott expects its per-share earnings to range from $1.05 to $1.09. The company expects full-year earnings in the range of $5.05 to $5.25 per share.
Abbott has won an innovation award for Lingo, its first consumer biowearable over-the-counter device that helps people ...
Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback